Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1803 in Relapsed/Refractory Multiple Myeloma with Extramedullary Plasmacytoma
NCT06952075Phase 2Recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Apr 2025
- Primary completion
- Jul 2027
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of velinotamig in multiple myeloma (MM), sponsored by Zhixiang Jintai. Started Apr 2025; status: recruiting.
02
Drugs
velinotamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06952075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952075.